{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:13Z","timestamp":1788388033087,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Science and Technology Projec","award":["WS202102"],"award-info":[{"award-number":["WS202102"]}]},{"name":"Young Talent Development Plan of Changzhou Health Commission"},{"name":"University Clinical Medical Science and Technology Development Fund of China","award":["JLY2021024"],"award-info":[{"award-number":["JLY2021024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The objective of this meta-analysis was to compare the efficacy and drug safety of tolvaptan with placebo for autosomal dominant polycystic kidney disease (ADPKD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The PubMed, Embase, and Cochrane Library databases were searched from inception to September 10, 2021. Eligible studies comparing tolvaptan and placebo in the treatment of patients with ADPKD were included. Data were analysed using Review Manager Version 5.3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirteen studies involving 3575 patients were included in the meta-analysis. Compared with placebo, tolvaptan had a better effect on delaying eGFR decline (MD 1.27, 95% CI 1.24\u20131.29, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) and TKV increase (MD \u2212\u00a03.01, 95% CI \u2212\u00a03.55 to \u2212\u00a02.47, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) in ADPKD treatment. Additionally, tolvaptan reduced the incidence of complications such as renal pain (OR 0.71, 95% CI 0.58\u20130.87, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), urinary tract infection (OR 0.69, 95% CI 0.54\u20130.89, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), haematuria (OR 0.68, 95% CI 0.51\u20130.89, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), and hypertension (OR 0.66, 95% CI 0.52\u20130.82, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). However, tolvaptan was associated with a higher incidence rate of adverse events such as thirst (OR 8.48 95% CI 4.53\u201315.87, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), polyuria (OR 4.71, 95% CI 2.17\u201310.24, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), and hepatic injury (OR 4.56, 95% CI 2.51\u20138.29, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tolvaptan can delay eGFR decline and TKV increase and reduce complications such as renal pain, urinary tract infection, haematuria, and hypertension in the treatment of ADPKD. However, tolvaptan increases the adverse effects of thirst, polyuria and hepatic injury.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-022-03353-8","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T10:06:09Z","timestamp":1662545169000},"page":"631-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis"],"prefix":"10.1007","volume":"55","author":[{"given":"Jingkui","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"1","key":"3353_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC et al (2018) Polycystic kidney disease. Nat Rev Dis Primers 4(1):50","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3353_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000449394","volume":"2","author":"C Sommerer","year":"2016","unstructured":"Sommerer C, Zeier M (2016) Clinical manifestation and management of ADPKD in western countries. Kidney Dis (Basel) 2(3):120\u2013127","journal-title":"Kidney Dis (Basel)"},{"key":"3353_CR3","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong AC, Devuyst O, Knebelmann B, Walz G et al (2015) ERA-EDTA Working Group for Inherited Kidney Diseases: autosomal dominant polycystic kidney disease: The changing face of clinical management. Lancet 385:1993\u20132002","journal-title":"Lancet"},{"key":"3353_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y et al (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287\u20131301","journal-title":"Lancet"},{"key":"3353_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ (2008) Autosomal dominant polycystic kidney disease. N Engl J Med 359:1477\u20131485","journal-title":"N Engl J Med"},{"key":"3353_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU et al (2015) Conference Participants: Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 88:17\u201327","journal-title":"Kidney Int"},{"issue":"10","key":"3353_CR7","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Perrone RD, Chapman AB et al (2018) A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 29(10):2458\u20132470","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3353_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/phar.1421","volume":"34","author":"BP Baur","year":"2014","unstructured":"Baur BP, Meaney CJ (2014) Review of tolvaptan for autosomal dominant polycystic kidney disease. Pharmacotherapy 34(6):605\u2013616","journal-title":"Pharmacotherapy"},{"issue":"11","key":"3353_CR9","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/ndt\/gfv422","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Meijer E, Chapman AB, TEMPO 3:4 Investigators et al (2016) Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant 31(11):1887\u20131894","journal-title":"Nephrol Dial Transplant"},{"key":"3353_CR10","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1097\/BRS.0000000000001061","volume":"40","author":"AD Furlan","year":"2015","unstructured":"Furlan AD, Malmivaara A, Chou R et al (2015) 2015 Updated method guideline for systematic reviews in the Cochrane back and neck group. Spine 40:1660\u20131673","journal-title":"Spine"},{"key":"3353_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605","journal-title":"Eur J Epidemiol"},{"issue":"8","key":"3353_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2215\/CJN.01520218","volume":"13","author":"ME Edwards","year":"2018","unstructured":"Edwards ME, Chebib FT, Irazabal MV et al (2018) Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 13(8):1153\u20131161","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"3353_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2174\/1570161118999200918094809","volume":"19","author":"S Lai","year":"2021","unstructured":"Lai S, Mangiulli M, Perrotta AM et al (2021) Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients on therapy with tolvaptan: a pilot study. Curr Vasc Pharmacol 19(5):556\u2013564","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"3353_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/j.ajkd.2016.08.028","volume":"69","author":"NF Casteleijn","year":"2017","unstructured":"Casteleijn NF, Blais JD, Chapman AB et al (2017) Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial. Am J Kidney Dis 69(2):210\u2013219","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3353_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres VE, Higashihara E, Devuyst O et al (2016) Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 11(5):803\u2013811","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"3353_CR16","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377(20):1930\u20131942","journal-title":"N Engl J Med"},{"issue":"25","key":"3353_CR17","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407\u20132418","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"3353_CR18","first-page":"363","volume":"34","author":"J Yamamoto","year":"2019","unstructured":"Yamamoto J, Nishio S, Kusunoki K et al (2019) Long-term treatment of tolvaptan for autosomal dominant polycystic kidney disease: a single centre retrospective cohort study. Nephrol Dial Transplant 34(Supplement 1):363\u2013376","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"3353_CR19","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2215\/CJN.03530411","volume":"6","author":"E Higashihara","year":"2011","unstructured":"Higashihara E, Torres VE, Chapman AB et al (2011) Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience. Clin J Am Soc Nephrol 6(10):2499\u20132507","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Supplement 1","key":"3353_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ndt\/gfy104.FP061","volume":"33","author":"H Kai","year":"2018","unstructured":"Kai H, Tsunoda R, Kawamura T et al (2018) A prospective study of the efficacy and adverse effectsof tolvaptan for autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant Nephrol DialmTransplant 33(Supplement 1):68","journal-title":"Nephrol Dial Transplant Nephrol DialmTransplant"},{"issue":"12","key":"3353_CR21","first-page":"2407","volume":"5","author":"RD Perrone","year":"2020","unstructured":"Perrone RD, Chapman AB, Oberdhan D et al (2020) The NOCTURNE randomized trial comparing 2 tolvaptan formulations [published correction appears in Kidney. Int Rep 5(12):2407\u20132408","journal-title":"Int Rep"},{"issue":"7","key":"3353_CR22","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1681\/ASN.2020101512","volume":"32","author":"JE Heida","year":"2021","unstructured":"Heida JE, Gansevoort RT, Torres VE et al (2021) The effect of tolvaptan on BP in polycystic kidney disease: a post hoc analysis of the TEMPO 3:4 Trial. J Am Soc Nephrol 32(7):1801\u20131812","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3353_CR23","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41390-020-0942-2","volume":"89","author":"R Raina","year":"2021","unstructured":"Raina R, Chakraborty R, Decoy ME et al (2021) Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression. Pediatric Res 89(4):894\u2013899","journal-title":"Pediatric Res"},{"issue":"5","key":"3353_CR24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10157-015-1086-2","volume":"19","author":"S Muto","year":"2015","unstructured":"Muto S, Kawano H, Higashihara E et al (2015) The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol 19(5):867\u2013877","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"3353_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/jcph.880","volume":"57","author":"SE Shoaf","year":"2017","unstructured":"Shoaf SE, Chapman AB, Torres VE et al (2017) Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial. J Clin Pharmacol 57(7):906\u2013917","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3353_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1053\/j.ajkd.2007.10.037","volume":"51","author":"BY Reed","year":"2008","unstructured":"Reed BY, McFann K, Bekheirnia MR et al (2008) Variation in age at ESRD in autosomal dominant polycystic kidney disease. Am J Kidney Dis 51(2):173\u2013183","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3353_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T et al (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31(3):337\u2013348","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3353_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2018","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33(3):477\u2013489","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"3353_CR29","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1681\/ASN.V1181505","volume":"11","author":"BF King","year":"2000","unstructured":"King BF, Reed JE, Bergstralh EJ et al (2000) Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11(8):1505\u20131511","journal-title":"J Am Soc Nephrol"},{"key":"3353_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2215\/CJN.00330705","volume":"1","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Chapman AB, Torres VE et al (2006) Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 1:148\u2013157","journal-title":"Clin J Am Soc Nephrol"},{"key":"3353_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ki.2011.119","volume":"80","author":"MV Irazabal","year":"2011","unstructured":"Irazabal MV, Torres VE, Hogan MC et al (2011) Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant kidney disease. Kidney Int 80:295\u2013301","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"3353_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MNH.0b013e328360a268","volume":"22","author":"Y Lotan","year":"2013","unstructured":"Lotan Y, Daudon M, Bruyere F et al (2013) Impact of fluid intake in the prevention of urinary system diseases: a brief review. Curr Opin Nephrol Hypertens 22(suppl 1):1\u201310","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3353_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","volume":"25","author":"T Miyazaki","year":"2007","unstructured":"Miyazaki T, Fujiki H, Yamamura Y et al (2007) Tolvaptan, an orally active vasopressin V(2)-receptor antagonist\u2014pharmacology and clinical trials. Cardiovasc Drug Rev 25:1\u201313","journal-title":"Cardiovasc Drug Rev"},{"issue":"4","key":"3353_CR34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1053\/j.ajkd.2015.04.044","volume":"66","author":"RD Perrone","year":"2015","unstructured":"Perrone RD, Neville J, Chapman AB et al (2015) Therapeutic area data standards for autosomal dominant polycystic kidney disease: a report from the polycystic kidney disease outcomes consortium (PKDOC). Am J Kidney Dis 66(4):583\u2013590","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3353_CR35","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","volume":"2","author":"RD Perrone","year":"2017","unstructured":"Perrone RD, Mouksassi MS, Romero K et al (2017) Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease [published correction appears in Kidney Int Rep. 2018 May 22;3(4):1015]. Kidney Int Rep. 2(3):442\u2013450","journal-title":"Kidney Int Rep."},{"issue":"1","key":"3353_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ et al (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26(1):160\u2013172","journal-title":"J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03353-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03353-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03353-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T10:14:57Z","timestamp":1677233697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03353-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["3353"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03353-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"13 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}